- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07650240
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (SPARKLE)
A Phase II Randomized Trial of Intermittent Androgen Deprivation Therapy Alone or Combined With [177Lu]Lu-PSMA-617, With or Without Abiraterone and Prednisone, in Patients With Low-Volume Metastatic Hormone-Sensitive Prostate Cancer
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited number of anatomic sites at the time of initial diagnosis (de novo low volume metastasis) or that has come back after a period of improvement (recurrent). Standard of care treatment for prostate cancer usually includes androgen deprivation therapy, with or without abiraterone acetate and prednisone. Leuprolide acetate is a form of androgen deprivation therapy. It blocks the body from making testosterone (a male hormone) and estradiol (a female hormone). It may stop the growth of prostate cancer cells that need testosterone to grow. 177Lu-PSMA-617 is a type of radioconjugate drug. Upon administration, vipivotide tetraxetan targets and binds to prostate specific membrane antigen (PSMA)-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is overexpressed on prostate tumor cells. Abiraterone acetate is a type of anti-androgen drug. It blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of cancer cells that need androgens to grow. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving 177Lu-PSMA-617 in combination with leuprolide acetate, with or without abiraterone acetate and prednisone, may be more effective at treating patients with recurrent or de novo low volume metastatic hormone-sensitive prostate cancer than giving leuprolide acetate alone.
Tutkimuksen yleiskatsaus
Tila
Ehdot
- Eturauhassyöpä
- Metastaattinen eturauhassyöpä
- Eturauhasen adenokarsinooma
- Pitkälle edennyt eturauhassyöpä
- Paikallinen eturauhassyöpä
- Vaihe IVB Eturauhassyöpä AJCC v8
- Eturauhasen adenokarsinooma
- Metastaattinen eturauhasen adenokarsinooma
- Pitkälle edennyt eturauhasen adenokarsinooma
- Toistuva eturauhasen adenokarsinooma
- Kastraatioherkkä eturauhassyöpä
- Metastaattinen hormoniherkkä eturauhassyöpä (mHSPC)
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Clinical Trials Referral Office
- Puhelinnumero: 855-776-0015
- Sähköposti: mayocliniccancerstudies@mayo.edu
Tutki yhteystietojen varmuuskopiointi
- Nimi: Urology Study Coordinator
- Puhelinnumero: 507-422-5076
Opiskelupaikat
-
-
Minnesota
-
Rochester, Minnesota, Yhdysvallat, 55905
- Rekrytointi
- Mayo Clinic in Rochester
-
Ottaa yhteyttä:
- Clinical Trials Referral Office
- Puhelinnumero: 855-776-0015
- Sähköposti: mayocliniccancerstudies@mayo.edu
-
Ottaa yhteyttä:
- Urology Study Coordinator
- Puhelinnumero: 507-422-5076
-
Päätutkija:
- Matthew K. Tollefson, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Male patients aged 18 years or older
-
Signed informed consent must be obtained prior to participation in the study
-
Histologically confirmed adenocarcinoma of the prostate
-
Prior treatment with radical prostatectomy or radiation therapy for localized disease is required
-
Prior treatment with ADT or androgen receptor pathway inhibitor (ARPI) or cytotoxic chemotherapy is permitted if:
- The last treatment > 12 months from enrollment on the trial
- The duration of treatment is less than 3 months and no evidence of disease progression on treatment
-
Disease detected on PSMA PET/CT scan [PSMA-avid low volume metastasis (LVM)]. Patients with standardized uptake value maximum (SUVMax) lesion/liver >1 [molecular imaging PSMA (miPSMA) score of 2] or lesion/parotid > 1 (miPSMA score of 3) would be included. PET scanners used in the study will comply with current guidelines established by the European Association of Nuclear Medicine (EANM) Research Limited (Ltd) (EARL) for harmonizing PET/CT image acquisition and reconstruction
-
Patients with hormone sensitive low volume metastatic disease (LVM); either de novo metastatic or recurrent disease. LVM, as assessed on PSMA PET/CT is defined as:
-
=< 10 total metastatic spots
- Lymph nodes with short axis of =< 2.5 cm
- Total tumor volume (TTV) < 200 mL
-
=< 4 bone metastases
-
No brain or liver metastases
-
-
Eastern Cooperative Oncology Group (ECOG) performance 0 - 2
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Absolute neutrophil count >= 1,500/mm^3
-
Serum bilirubin =< 1.5 x upper limit of normal (ULN)
-
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 2.5 x ULN
-
Serum creatinine =< 1.5 x ULN or an estimated glomerular filtration rate (eGFR) >= 50 mL/min/1.73m^2
-
Able to start therapy within 28 days of screening
-
Expected life expectancy > 6 months
Exclusion Criteria:
-
PSMA-undetectable disease defined as rising prostate specific antigen (PSA) with absence of PSMA-positive lesions in PSMA PET/CT imaging
-
PSMA-negative disease defined as lesions detected on imaging that are deemed concerning for active cancer metastasis with PSMA SUVmax less than liver and meeting specific size criteria: lymph nodes with short axis of >= 2.5 cm, visceral lesions with a solid appearance (soft tissue density) >= 1 cm, and bone metastases with a measurable soft tissue component >= 1 cm
-
Patient with in-field failure (disease recurrence in prostate bed after primary definitive prostatectomy or radiotherapy)
-
Patient with spinal metastatic disease-causing cord compression
-
Patient with prior disease progression on ADT [castration resistance prostate cancer (CRPC)]
-
Prior treatment with ADT or cytotoxic chemotherapy or ARPI within less than 12 months from enrollment on the trial
-
Prior treatment with ADT or ARPI or cytotoxic chemotherapy is permitted only if more than 3 months treatment duration and no evidence of disease progression on treatment
-
Patients with severe [Common Terminology Criteria for Adverse Events (CTCAE) grade > 2] xerostomia
-
Patients with well documented history of myelosuppression or renal disease that might impair their participation in the trial per medical advice
-
Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible
-
Estimated life expectancy < 6 months
-
Concurrent serious medical co-morbidities as determined by study investigator and expected to impair participation in the study
- Subjects with female partners of reproductive potential are required to use effective, medically acceptable methods of birth control (e.g., spermicide in conjunction with a barrier such as a condom or sexual abstinence) while on this study, and for 14 weeks after the last dose of 177Lu-PSMA-617
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Arm A1 (177Lu-PSMA-617, iADT)
Patients receive 177Lu-PSMA-617 IV once every 6 weeks and leuprolide acetate subcutaneous (SC) once every 3 months (Q3M). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study. |
Ancillary studies
Muut nimet:
Undergo collection of blood samples
Muut nimet:
Given IV
Muut nimet:
Given SC
Muut nimet:
Undergo PSMA PET/CT
Muut nimet:
Undergo SPECT
Muut nimet:
|
|
Active Comparator: Arm A2 (iADT)
Patients receive leuprolide acetate SC Q3M for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial. |
Ancillary studies
Muut nimet:
Undergo collection of blood samples
Muut nimet:
Given SC
Muut nimet:
Undergo PSMA PET/CT
Muut nimet:
|
|
Kokeellinen: Arm B1 (177Lu-PSMA-617, iADT, iAA, P)
Patients receive 177Lu-PSMA-617 IV every 6 weeks, leuprolide acetate SC Q3M, abiraterone acetate PO (by mouth) QD (once a day) and prednisone PO BID (twice a day). Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial and undergo SPECT on study. |
Ancillary studies
Muut nimet:
Given PO
Muut nimet:
Undergo collection of blood samples
Muut nimet:
Given PO
Muut nimet:
Given IV
Muut nimet:
Given SC
Muut nimet:
Undergo PSMA PET/CT
Muut nimet:
Undergo SPECT
Muut nimet:
|
|
Active Comparator: Arm B2 (iADT, iAA, P)
Patients receive leuprolide acetate SC Q3M, abiraterone acetate PO QD and prednisone PO BID. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo PSMA PET/CT and collection of blood samples throughout the trial. |
Ancillary studies
Muut nimet:
Given PO
Muut nimet:
Undergo collection of blood samples
Muut nimet:
Given PO
Muut nimet:
Given SC
Muut nimet:
Undergo PSMA PET/CT
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Radiographic progression free survival (rPFS)
Aikaikkuna: At 18 months
|
Will be evaluated according to prostate specific membrane antigen (PSMA) positron emission tomography (PET) progression (PPP) criteria. Defined as the time from enrollment to documented radiographic progression or death from any cause, whichever occurs first. |
At 18 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Biochemical recurrence free survival (BCR-FS)
Aikaikkuna: At 12 months
|
Assessed using PSMA scans. Defined as the time after treatment during which no signs of biochemical recurrence are found. |
At 12 months
|
|
Treatment-free interval
Aikaikkuna: Up to 18 months
|
Defined as the length of time a patient remains off active systemic therapies while maintaining disease control. |
Up to 18 months
|
|
Overall survival
Aikaikkuna: Up to 3 years
|
Defined as the time from randomization or enrollment to death from any cause, whichever occurs first. |
Up to 3 years
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Quality of life - FACT-P
Aikaikkuna: At baseline and then every 3 months up to 1 year
|
Assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, a 39-item questionnaire used to measures Health-Related Quality of Life (HRQOL) in prostate cancer patients. Responses to each question are scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Possible total scores range from 0-156, with higher scores indicating better QoL. A drop in the FACT-P total score >5 points will be considered clinically meaningful. |
At baseline and then every 3 months up to 1 year
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Matthew K. Tollefson, MD, Mayo Clinic in Rochester
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Sukuelinten sairaudet
- Sukuelinten kasvaimet, mies
- Urogenitaaliset kasvaimet
- Neoplasmat sivustoittain
- Neoplasmat
- Sukuelinten sairaudet, mies
- Eturauhasen sairaudet
- Miesten urogenitaaliset sairaudet
- Eturauhasen kasvaimet
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Aivolisäkkeen vapauttavat hormonit
- Hypotalamuksen hormonit
- Peptidihormonit
- Neuropeptidit
- Peptidit
- Aminohapot, peptidit ja proteiinit
- Oligopeptidit
- Hermokudosproteiinit
- Proteiinit
- Tutkintatekniikat
- Kliiniset laboratoriotekniikat
- Diagnostiikkatekniikat ja menettelyt
- Diagnoosi
- Fyysiset ilmiöt
- Polisykliset yhdisteet
- Raskaat
- Raskaat
- Steroidit
- Sulatettu rengasyhdisteet
- Raskaat
- Sähkömagneettiset ilmiöt
- Magneettiset ilmiöt
- Androstenes
- Androstanes
- Sähkömagneettinen säteily
- Säteily
- Säteily, ionisoiva
- Elementtipartikkelit
- Valaistus
- Optiset ilmiöt
- Säteily, ionisoiva
- Gonadotropiinia vapauttava hormoni
- Abirateroniasetaatti
- Pluvicto
- Prednisoni
- Leuprolidi
- luprolidiasetaattigeelivarasto
- Näytteenkäsittely
- Röntgenkuva
- Fotonit
- deltacortene
- harrastus
Muut tutkimustunnusnumerot
- MC250507
- 25-008953 (Muu tunniste: Mayo Clinic Institutional Review Board)
- SPARKLE (Muu tunniste: Mayo Clinic Urology)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .